Lantheus closes $350M acquisition of Life Molecular Imaging; names Dr. Dinkelborg as Head of R&D

Lantheus Holdings, Inc.

Completed acquisition of Life Molecular for $350M cash after adjustments, gaining Alzheimer's PET agent Neuraceq.
Appointed Dr. Ludger Dinkelborg, former Life Molecular CEO, as Head of R&D effective Aug 1, 2025.
Transaction adds commercial infrastructure, R&D capabilities, and international footprint for Alzheimer's radiodiagnostics.
Dinkelborg will oversee Clinical Development, Regulatory Affairs, Clinical Operations, Program Management, and AI/Biomarkers.

item 2.01item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.